Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...

Tuesday, financial research firm Cantor Fitzgerald maintained a Neutral stock rating for Desktop Metal Inc. (NYSE:DM) with a consistent price target of $5.00. The firm's analysts highlighted that ...

A U.S. Senate committee voted on Wednesday to advance President Donald Trump's nominee Howard Lutnick, billionaire chairman ...

President Trump has nominated Pierre Gentin, chief legal officer of the consulting giant McKinsey & Co. since 2019, to serve ...

Toni Fitzgerald is a Pennsylvania-based reporter who has covered the media industry since 2002. She currently focuses her coverage on streaming and book publishing. She also works as a freelance ...

Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" ...

A slew of space stocks have skyrocketed following the inauguration of President Trump, boosted by his vow to champion American space exploration during his administration. Set against this ...

Cantor Fitzgerald assumed coverage of Cidara Therapeutics (CDTX) with an Overweight rating. Cidara’s lead asset CD388, an anti-viral that targets neuraminidase, an essential surface receptor ...

Cantor Fitzgerald has a “Hold” rating and a $72.00 price objective on the stock. The consensus estimate for Palantir Technologies’ current full-year earnings is $0.20 per share. Get Palantir ...

Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Fate Therapeutics in a report issued on Tuesday ...